Hologic says its integration of Gen-Probe after acquiring the diagnostics company is going so well that it will accelerate planned organizational changes. Hologic announced
that Carl Hull will retire from his position as senior vice president and general manager of diagnostics ahead of schedule but will continue as a consultant until mid-August 2013. Gen-Probe became a wholly owned subsidiary of Hologic following completion of the $3.8 billion-acquisition in August 2012. Hull had served as Gen-Probe’s chairman, president, and CEO before the transaction.
In other personnel changes, Hologic appointed Rohan Hastie senior vice president and group general manager-diagnostics. Hastie is the former vice president and general manager in the women’s health group of Hologic’s diagnostic unit. In his new position he will oversee women’s health and virology businesses as well as U.S. diagnostics sales. Eric Tardif, senior vice president of commercial operations-diagnostics will become senior vice president of corporate strategy.
Hologic expects to save more than $40 million in costs by the end of the first year after the acquisition. An additional $35 million in cost savings are expected by the end of 2015, the company says. Hologic says it will take advantage of cross-selling opportunities for its expanded molecular diagnostics product line through its global sales and marketing reach.